EUVIMEDEUVIMED entdecken
Open Access

Remission Assessment by Circulating Tumor DNA in Large B-Cell Lymphoma

Mark Roschewski iD, David M Kurtz iD, Jason R Westin iD, Ryan C Lynch iD, Ajay K Gopal iD, Stefan K Alig iD, Brian J Sworder iD, Hua-Jay J Cherng iD, Christian Kuffer iD, Derek Blair, Krystal Brown iD, Jordan S Goldstein iD und 6 weitere

Journal of Clinical Oncology · 2025-12 · 43 (34) · 3652-3661

DOI: 10.1200/jco-25-01534 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Oncology, 2025-12. Verfasst von Mark Roschewski und 17 weiteren Autor:innen. Beteiligte Einrichtung: Lymphoid Malignancies Branch, National Cancer Institute, Bethesda, MD. Hauptthemen laut MEDLINE: Circulating Tumor DNA, Lymphoma, Large B-Cell, Diffuse, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Large B-cell lymphomas (LBCLs) are curable, but patients with residual disease after therapy invariably experience progression. Ultrasensitive methods to detect circulating tumor DNA (ctDNA) as minimal residual disease (MRD) may improve the determination of remission. METHODS We integrated data from five prospective studies of frontline anthracycline-based chemotherapy in patients with LBCL. Tumor-specific phased variants were identified from pretreatment samples and monitored at landmark time points. Serial plasma specimens were blindly analyzed for detectable ctDNA as MRD. MRD status was compared with conventional response criteria for prognosis of progression-free survival (PFS). RESULTS We studied ctDNA-MRD in 137 patients by monitoring 409 plasma specimens over time. Detectable ctDNA rates decreased during therapy with 55% and 78% of patients achieving undetectable ctDNA after two cycles and at the end of therapy, respectively. After a median follow-up of 37 months, the 2-year PFS for patients with detectable versus undetectable ctDNA after two cycles was 67% versus 96% ( P = .0025; hazard ratio [HR], 6.9) and after therapy was 29% versus 97% ( P < .0001; HR, 28.7), respectively. Ninety-two (94%) patients with undetectable ctDNA at the end of therapy remained alive without progression, while 19 (68%) patients with detectable ctDNA progressed or died. MRD status at the end of therapy had greater prognostic utility than conventional lymphoma response criteria using positron emission tomography (PET) scans (HR, 3.6 for positive PET and 28.3 for detectable ctDNA). CONCLUSION Ultrasensitive ctDNA detection after frontline LBCL therapy is more prognostic than conventional radiographic response criteria. A refined definition of remission with ctDNA-MRD may improve clinical and psychological outcomes for patients with LBCL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Circulating Tumor DNALymphoma, Large B-Cell, DiffuseAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorHumansMaleFemaleMiddle AgedNeoplasm, ResidualAgedProspective StudiesAdultRemission InductionAnthracyclinesProgression-Free SurvivalAged, 80 and over

Substanzen

Circulating Tumor DNABiomarkers, TumorAnthracyclines

Autor:innen und Institutionen

  • Lymphoid Malignancies Branch, National Cancer Institute, Bethesda, MD.
  • Division of Oncology, Department of Medicine, Stanford University, Stanford, CA.
  • Stanford Cancer Institute, Stanford University, Stanford, CA.
  • Foresight Diagnostics, Boulder, CO.
  • Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Division of Hematology Oncology, Department of Medicine, University of Washington School of Medicine Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.

ORCID-Profile: Mark Roschewski, David M Kurtz, Jason R Westin, Ryan C Lynch, Ajay K Gopal, Stefan K Alig, Brian J Sworder, Hua-Jay J Cherng, Christian Kuffer, Krystal Brown, Jordan S Goldstein, Maximilian Diehn, Wyndham H Wilson, Ash A Alizadeh

Förderung

  • NCI NIH HHS

Zitieren

APA

Roschewski, M., Kurtz, D. M., Westin, J. R., Lynch, R. C., Gopal, A. K., Alig, S. K., Sworder, B. J., Cherng, H. J., Kuffer, C., Blair, D., Brown, K., Goldstein, J. S., Schultz, A., Close, S., Chabon, J. J., Diehn, M., Wilson, W. H., & Alizadeh, A. A. (2025). Remission Assessment by Circulating Tumor DNA in Large B-Cell Lymphoma. Journal of Clinical Oncology, 43(34), 3652-3661. https://doi.org/10.1200/jco-25-01534

Vancouver

Roschewski M, Kurtz DM, Westin JR, Lynch RC, Gopal AK, Alig SK, et al. Remission Assessment by Circulating Tumor DNA in Large B-Cell Lymphoma. Journal of Clinical Oncology. 2025;43(34):3652-3661. doi:10.1200/jco-25-01534

BibTeX
@article{Roschewski2025,
  author = {Roschewski, Mark and Kurtz, David M and Westin, Jason R and Lynch, Ryan C and Gopal, Ajay K and Alig, Stefan K and Sworder, Brian J and Cherng, Hua-Jay J and Kuffer, Christian and Blair, Derek and Brown, Krystal and Goldstein, Jordan S and Schultz, Andre and Close, Sandra and Chabon, Jacob J and Diehn, Maximilian and Wilson, Wyndham H and Alizadeh, Ash A},
  title = {Remission Assessment by Circulating Tumor DNA in Large B-Cell Lymphoma},
  journal = {Journal of Clinical Oncology},
  year = {2025},
  volume = {43},
  number = {34},
  pages = {3652--3661},
  doi = {10.1200/jco-25-01534}
}
Kostenlos starten →